News
-
Iranian Blood Transfusion Organization Newsletter – August 2020
The Iranian Blood Transfusion Organization (IBTO) and its most recent activities are featured on TIF’S website.
Read More » -
COVID-19 Update: Here’s Where We Stand Now In the Race For A Vaccine
As large parts of the world prepare for a second wave of coronavirus cases governments have pinned their hopes on the rapid development of a vaccine to provide a route…
Read More » -
eThalED COURSE: Heart Disease in Thalassaemia by Prof. Malcolm Walker
Last -but not least- in our eThalED Webinar Series for Medical Specialists comes ‘Heart Disease in Thalassaemia’, one the major causes of morbidity and mortality among patients with this severe…
Read More » -
Revisiting The Use and Management of Blood in Europe in Times of Crisis and Beyond
About 25 million blood transfusions are administered to patients every year throughout the European Union. What may come to mind to most people when thinking about blood transfusion is acute…
Read More » -
AstraZeneca Resumes Final Stage Trials For Its Covid-19 vaccine After Initial Halt
AstraZeneca Plc and the University of Oxford have resumed the British clinical trials of its Covid-19 vaccine, after the initial suspension over concerns with a participant who fell ill. University…
Read More » -
The ”International Blood Diseases Symposium” Is Just Around The Corner
The Turkish Federation of Blood Diseases, Kan Hastalıkları Federasyonu is joining forces with TIF for the organisation of the ”International Blood Diseases Virtual Symposium”, which will be held virtually on…
Read More » -
Coming Up: A TIF Live Webinar on ”Heart Disease in Thalassaemia”
Tune in with TIF on Tuesday, 15 September 2020, 15:00 EEST, for one of the last webinars from the TIF eThalED series for Healthcare Professionals! The topic to be brought…
Read More » -
AstraZeneca Puts Leading COVID-19 Vaccine Trial On Hold
The pharmaceutical company AstraZeneca halted large, late-stage global trials of its coronavirus vaccine on Tuesday, because of a serious suspected adverse reaction in a participant. It is not yet known…
Read More » -

